Early Detection and Screening Working Group
Christina Clarke Dur, PhD
Vice President, Epidemiology and Distinguished Scientist
GRAIL
Co-Chairs
Bree Mitchell, PhD
Senior Director, Translational Medicine and Innovation
Natera
Current Projects
Framework for clinical validation and checklist of metrics and contextual information necessary for various stakeholders to interpret performance across different technologies or tests
AACR 2026 Session
BLOODPAC Session 4/18/26 at 2:30-4:00 PM: Contextual Challenges in Interpreting Performance of Blood-Based Early Cancer Detection Tests: A BLOODPAC Perspective
Participating Organizations
AOA Dx, Association for Molecular Pathology (AMP), AstraZeneca, Bio-Rad, Bristol Myers Squibb (BMS), Delfi Diagnostics, Exact Sciences, Friends of Cancer Research, Grail, Guardant Health, International Society of Liquid Biopsy (ISLB), Loxo Oncology, Lungevity, Merck, Natera, NeoGenomics, NIH / NCI, Novartis, PreAnalytiX, Prevent Cancer Foundation, Roche, Tecan, Ultima Genomics
Past Deliverables
Previous Co-chair: Girish Putcha (Freenome)
Previous Co-chair: Girish Putcha (Freenome)
Meetings
This working group meets on zoom every other Wednesday from 1:00 - 2:00 PM EST.
Special workshops and sessions:
Not applicable at this time.